Navigation Links
Osseon Receives Second Patent Allowance for Minimally Invasive Vertebral Compression Fracture Treatment Devices
Date:10/4/2010

SANTA ROSA, Calif., Oct. 4 /PRNewswire/ -- Osseon Therapeutics, Inc., a biomedical device company based in Santa Rosa, California, received its second patent Notice of Allowance (NOA) for its spinal vertebral compression fracture (VCF) technology.  The company, which was started in 2006, now has two allowed and twelve additional patent applications pending in the United States, and several others throughout the world for spinal therapies and devices.  

The company has been marketing its FDA and CE Mark cleared "Osseoplasty™" system in the U.S. and Europe, since February, 2009 and February, 2010, respectively.  The proprietary Osseoplasty™ procedure has been performed in over 1,100 patients in the U.S. and Europe.

According to John Stalcup, Ph.D., President and CEO of Osseon, "This second patent allowance for Osseon's spinal VCF technology is another cornerstone for the company's intellectual property foundation.  We continue to strengthen our intellectual property position and strive to obtain additional patents in the future on various aspects of the Osseoflex® steerable and curvable needle and the novel methods for bone cement delivery, which enable a safe, effective, and minimally invasive approach for spine disease treatment."

ABOUT Osseon Therapeutics, Inc.

About Osseon

Osseon Therapeutics, Inc. focuses on bringing to market alternative minimally invasive treatments for degenerative bone and joint disease. Headquartered in Santa Rosa, CA, the company's groundbreaking technology and delivery system provides comparable or better efficacy and safety than other commercial solutions while offering significant advantages in efficiency and cost. By improving the treatment of compression fractures within the thoracic and lumbar vertebral spine, Osseon offers alternative solutions to patients suffering from these maladies, as well as the physicians and medical facilities that treat them. Its first-generation products have received both FDA clearance and the CE Mark for product distribution in the United States and European Union.  For more information, visit our web site at www.osseon.com.

Osseon®  and Osseoflex® are registered trademarks, and Osseoplasty™ is a trademark of Osseon Therapeutics, Inc. The names of actual companies and products mentioned herein may be the trademarks of their respective owners.


'/>"/>
SOURCE Osseon Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Osseon Receives Patent Allowance for Novel Spinal VCF Treatment Devices
2. Osseon Therapeutics Demonstrates to the European Medical Community How to Think Outside The Balloon When Treating Vertebral Compression Fractures
3. Osseon Launches in Europe
4. Prognosis Health Information Systems ChartAccess 4.0 Receives ONC-ATCB 2011/2012 Certification
5. Mylan Receives Approval for Fludarabine Phosphate Injection, USP
6. WATCHMAN® Receives German Reimbursement Coverage
7. Lingohocken Fire Company Receives PAD Donation After Recent Rescue at Fox Heath Farm
8. Abbott Receives FDA Market Clearance for Next-Generation Contact Lens Disinfecting Solution
9. Advanced Life Sciences Receives $1.5 Million From Exercise of Unit Warrants and Secures Financing Commitment
10. China Shenghuo Receives Notice from NYSE Amex LLC Regarding Listing Standards
11. Progenika Receives CE Mark for First DNA Chip to Detect Mutations in Lipoprotein Lipase (LPL) Gene
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 23, 2017 Summary ... disease pipeline guide Primary Hyperoxaluria - Pipeline Review, ... Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline ... characterized by recurrent kidney and bladder stones. It ... oxalate. Symptoms include blood in the urine, pain ...
(Date:3/23/2017)... and VANCOUVER, British Columbia ... SPHS ) (the "Company" or "Sophiris"), a ... treatment of urological diseases, today announced that data from ... the drug as a focal treatment for localized prostate ... 26, 2017 at the 32 nd Annual European ...
(Date:3/23/2017)...   Icertis , the leading provider of ... today announced an upgrade to the Icertis Clinical ... clinical trials contract management. Built on the ... speeds up clinical trial contracting while improving collaboration ... "The pharmaceutical industry is under intense ...
Breaking Medicine Technology:
(Date:3/25/2017)... ... March 25, 2017 , ... Getting earned media coverage meaningful for Garden Media ... All through the year, Garden Media aims to provide material helpful to clients’ goals ... pitching client’s key messages to gain coveted media placements, Garden Media wows ...
(Date:3/24/2017)... ... March 24, 2017 , ... Mediaplanet ... a conversation on the current obstacles facing infection prevention and offer strategies for ... caused by these infections. , The print component of “Fighting Infection” is ...
(Date:3/24/2017)... ... ... According to a new study by NCPA Senior Fellow John R. Graham, ... Congress has directed the CBO to follow. The CBO itself previously recognized Obamacare would ... estimates a reduction in employer-based coverage due to the GOP reform, which is not ...
(Date:3/24/2017)... ... March 24, 2017 , ... Shamanic healer and teacher ... Healing and Spiritual Awakening, proudly presents her Sacred Peru retreat with world ... and spiritual journey during the Summer Solstice will also be her final international ...
(Date:3/24/2017)... CA (PRWEB) , ... March 24, 2017 , ... ... on two panels at the Advanced ERISA Benefit Claims Litigation seminar in Chicago, ... Creating the Administrative Record, The majority of cases litigated under ERISA involve claims ...
Breaking Medicine News(10 mins):